Total Funding
76
58
Total FundingSeries A raised
Growth Score 76 in past quarter
-8 pts
Heat Score 58 in past quarter
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
29580
NanoPhoria develops non-viral, nano-delivery systems for cardiovascular treatments, focusing on inhalable biologics.
- Claudio De Luca: Co-Founder & CEO
- Daniele Catalucci: Co-Founder, Senior Scientific Advisor, and CSO ad interim
About the Company
NanoPhoria is a biotechnology company focused on the development of innovative cardiovascular treatments. It specializes in a non-viral, nano-in-micro delivery system for biologics, designed to target the heart directly. This preclinical-stage company is exploring the potential of inhalable therapies, utilizing tissue-directed delivery methods for
therapeutic peptides and RNAs. NanoPhoria's approach aims to revolutionize the treatment of cardiovascular diseases by offering a versatile, non-viral drug delivery platform, formulated for both inhalation and other administration routes. With a dedicated team, NanoPhoria is committed to advancing cardiovascular health through groundbreaking research and development.